Kechell Pharma Secures Over $1.3 Billion Deal for Dual-Target CAR-T Therapy KQ-2003 in Global Licensing Agreement

In addition, the agreement also grants ERIGEN the use of key patent structures and sequences of KQ-2003 for development."Universal CAR-T Cell Therapy"The rights. According to the agreement arrangement,Novatim Retains Full Rights to This Universal Product in Greater China, laying the foundation for subsequent joint development and regional commercialization.

According to the terms of the collaboration, Novatim will obtain$15 millionRecent development milestone payments, and is eligible to receive a total amount of up to$1.32 billionMilestone payments for the development, registration, and commercialization phases. In addition, Novatim will also receive a maximum amount based on the net sales of KQ-2003 in the licensed region.$800 millionSales split.

KQ-2003 is an innovative therapy developed by Novatim based on the enhanced dual-target CAR-T platform. Through parallel structural design and signal domain optimization, it significantly enhances the persistence and anti-tumor activity of CAR-T cells while reducing the risk of recurrence associated with traditional CAR-T therapies.

Its core advantages include: excellent efficacy, safety advantages, and cost competitiveness, currently inRelapsed/Refractory Multiple Myeloma（rrMM）and POEMS SyndromePromising efficacy was achieved in registrational clinical trials.